Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 Jan 15;122(2):230-7.
doi: 10.1002/cncr.29732. Epub 2015 Oct 20.

Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative

Farzana Pashankar  1 , Juliet P Hale  2 , Ha Dang  3 , Mark Krailo  4 , William E Brady  5 , Carlos Rodriguez-Galindo  6 , James C Nicholson  7 , Matthew J Murray  7 , Deborah F Bilmire  8 , Sara Stoneham  9 , G Suren Arul  10 , Thomas A Olson  11 , Daniel Stark  12 , Furqan Shaikh  13 , James F Amatruda  14   15 , Allan Covens  13 , David M Gershenson  16 , A Lindsay Frazier  6
Affiliations
Comparative Study

Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative

Farzana Pashankar et al. Cancer. .

Erratum in

Abstract

Background: There is a debate regarding the management of ovarian immature teratomas (ITs). In adult women, postoperative chemotherapy is standard except for stage I, grade 1 disease, whereas surgery alone is standard in pediatric patients. To determine the role of chemotherapy, a pooled analysis of pediatric and adult clinical trials was conducted.

Methods: Data from 7 pediatric trials and 2 adult trials were merged in the Malignant Germ Cell International Collaborative data set. Four trials included patients with newly diagnosed pure ovarian ITs and were selected (Pediatric Oncology Group/Children's Cancer Group Intergroup Study (INT 0106), Second UKCCSG Germ Cell Tumor Study (GC2), Gynecologic Oncology Group (GOG 0078 and GOG 0090). Adult and pediatric trials were analyzed separately. The primary outcome measures were event-free survival (EFS) and overall survival (OS).

Results: One hundred seventy-nine patients were included (98 pediatric patients and 81 adult patients). Ninety pediatric patients were treated with surgery alone, whereas all adult patients received chemotherapy. The 5-year EFS and OS were 91% and 99%, respectively, for the pediatric cohort and 87% and 93%, respectively, for the adults. There were no relapses in grade 1 patients, regardless of the stage or age. Only 1 adult patient with a grade 2 IT relapsed. Among grade 3 patients, the 5-year EFS was 0.92 (0.72-0.98) for stage I/II and 0.52 (0.22-0.75) for stage III in the pediatric cohort (P = .005) and 0.91 (0.69-0.98) for stage I/II and 0.65 (0.39-0.83) for stage III/IV in the adult cohort (P = .01). Postoperative chemotherapy did not decrease relapses in the pediatric cohort.

Conclusions: The grade was the most important risk factor for relapse in ovarian ITs. Among grade 3 patients, the stage was significantly associated with relapse. Adjuvant chemotherapy did not decrease relapses in the pediatric cohort; its role in adults remains unresolved. Cancer 2016;122:230-237. © 2015 American Cancer Society.

Keywords: adult; chemotherapy; ovarian immature teratoma; pediatric.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES The authors made no disclosures.

Figures

Figure 1
Figure 1
Event-free survival for pediatric patients with ovarian grade 3 immature teratomas by stage. Pediatric patients with grade 3, stage I/II ovarian immature teratomas had a significantly reduced risk for an event-free survival event in comparison with patients with grade 3, stage III disease.
Figure 2
Figure 2
EFS and OS for adult patients with grade 3 ovarian immature teratomas by stage. Adult patients with grade 3, stage I/II ovarian immature teratomas had a significantly reduced risk for an EFS event in comparison with patients with grade 3, stage III/IV disease. OS was not significantly different between the 2 groups. EFS indicates event-free survival; OS, overall survival.
See this image and copyright information in PMC

Comment in

References

    1. Gobel U, Calaminus G, Blohm M, et al. Extracranial non-testicular teratoma in childhood and adolescence: introduction of a risk score for stratification of therapy. Klin Padiatr. 1997;209:228–234. - PubMed
    1. Heifetz SA, Cushing B, Giller R, et al. Immature teratomas in children: pathologic considerations. Am J Surg Pathol. 1998;22:1115–1124. - PubMed
    1. Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer. 1976;37:2359–2372. - PubMed
    1. Gershenson DM, del Junco G, Silva EG, Copeland LJ, Wharton JT, Rutledge FN. Immature teratoma of ovary. Obstet Gynecol. 1986;68:624–629. - PubMed
    1. Cushing B, Giller R, Ablin A, et al. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the Pediatric Oncology Group and the Children’s Cancer Group. Am J Obstet Gynecol. 1999;181:353–358. - PubMed

Publication types

MeSH terms